Plain-English translation of NCT06755632 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether offering liver disease screening at community health centers can catch serious liver problems early. Researchers will use a quick, painless ultrasound technique called Fibroscan and rapid blood tests to check for signs of liver scarring and viral hepatitis B and C infections. If your results suggest liver disease, you'll be referred to a specialist for follow-up care.
Many people with early liver disease don't know they have it because they have no symptoms. This study aims to find these cases early, before serious damage develops, so people can get treatment and prevent complications.
You likely qualify if…
You likely don't qualify if…
On your visit to the health center, a traveling doctor will offer you two simple tests: a Fibroscan ultrasound (a painless device that measures liver stiffness) and quick blood tests for hepatitis. The whole visit should take 30 minutes or less. If your results show signs of liver disease, you'll receive an appointment referral to a hospital liver specialist for further evaluation.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
France
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment target
~600 participants
Started
June 2025
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Veronique GRANDO, MD-PhD
Assistance Publique - Hôpitaux de Paris
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.